← Leaderboards
Dawn S Milliner
Mayo Clinic Coll Of Medicine, Rochester
$4,368,957
Attributed
$4,368,957
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2005–18$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$16,707,892 · 8
By mechanism
U54$14,899,131 · 2
R01$1,789,207 · 1
R13$16,500 · 1
M01$3,054 · 4
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Medicine, Rochester
Same institution · by research overlap
- Michael J Yaszemski$10,057,008
- Carla G Monico$600,130
- Michael J Moore$2,819,462
- Moses Rodriguez$7,609,151
- Rajiv Kumar$7,413,406
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchRenal FunctionKidney FailureInjuryChildhoodNephrocalcinosisInternationalRegistriesScientistKidneyOnline SystemsHyperoxaluriaClinical TrialsCohortEnd Stage Renal FailureInheritedNephrolithiasisPhysiciansOxalatesEffective TherapyPatient CareCystinuriaDatabasesOxalosis
Grant awards (32)
Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium$1,228,476
U54 · FY2018 · DK · contact PI
Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium$1,231,835
U54 · FY2017 · DK · contact PI
Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium$1,235,096
U54 · FY2016 · DK · contact PI
Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium$1,237,615
U54 · FY2015 · DK · contact PI
Nephrolithiasis and Kidney Failure: the Rare Kidney Stone Consortium$1,250,000
U54 · FY2014 · DK · contact PI
Hereditary Causes of Nephrolithaisis and Kidney Failure$1,222,963
U54 · FY2013 · DK · contact PI
Primary Hyperoxaluria$545,814
U54 · FY2013 · DK · contact PI
Hereditary Causes of Nephrolithaisis and Kidney Failure$1,224,428
U54 · FY2012 · DK · contact PI
Primary Hyperoxaluria$502,906
U54 · FY2012 · DK · contact PI
Hereditary Causes of Nephrolithaisis and Kidney Failure$1,229,144
U54 · FY2011 · DK · contact PI
Primary Hyperoxaluria$501,483
U54 · FY2011 · DK · contact PI
Hereditary Causes of Nephrolithaisis and Kidney Failure$1,230,037
U54 · FY2010 · DK · contact PI
Primary Hyperoxaluria$505,017
U54 · FY2010 · DK · contact PI
Hereditary Causes of Nephrolithaisis and Kidney Failure$1,249,341
U54 · FY2009 · DK · contact PI
Primary Hyperoxaluria$504,976
U54 · FY2009 · DK · contact PI
Prevention of Renal Damage in Primary Hyperoxaluria$443,735
R01 · FY2008 · DK · contact PI
Prevention of Renal Damage in Primary Hyperoxaluria$444,161
R01 · FY2007 · DK · contact PI
Prevention of Renal Damage in Primary Hyperoxaluria$446,637
R01 · FY2006 · DK · contact PI
Prevention of Renal Damage in Primary Hyperoxaluria$454,674
R01 · FY2005 · DK
7th International Workshop on Primary Hyperoxaluria$16,500
R13 · FY2005 · DK
DETERMINATION OF WBC CYSTINOSIS$1,658
M01 · FY2005 · RR
INVESTIGATIONS INTO THE PHENOTYPE AND GENOTYPE OF ATYPICAL PRIMARY$237
M01 · FY2005 · RR
Determination of WBC Cystinosis$1,159
M01 · FY2004 · RR
INTRAVENOUS GAMMA GLOBULIN AS AN AGENT TO LOWER ALLOSENSITIZATION$0
M01 · FY2002 · RR
INVESTIGATIONS INTO PHENOTYPE &GENOTYPE OF ATYPICAL PRIMARY HYPEROXALURIA$0
M01 · FY2002 · RR
COMPASSIONATE USE OF CYSTEAMINE IN NEPHROPATHIC CYSTENOSIS$0
M01 · FY2002 · RR
INTRAVENOUS GAMMA GLOBULIN AS AN AGENT TO LOWER ALLOSENSITIZATION$0
M01 · FY2001 · RR
INVESTIGATIONS INTO PHENOTYPE &GENOTYPE OF ATYPICAL PRIMARY HYPEROXALURIA$0
M01 · FY2001 · RR
COMPASSIONATE USE OF CYSTEAMINE IN NEPHROPATHIC CYSTENOSIS$0
M01 · FY2001 · RR
INTRAVENOUS GAMMA GLOBULIN AS AN AGENT TO LOWER ALLOSENSITIZATION$0
M01 · FY2000 · RR
INVESTIGATIONS INTO PHENOTYPE &GENOTYPE OF ATYPICAL PRIMARY HYPEROXALURIA$0
M01 · FY2000 · RR
COMPASSIONATE USE OF CYSTEAMINE IN NEPHROPATHIC CYSTENOSIS$0
M01 · FY2000 · RR